Home Labile glycated hemoglobin: an underestimated laboratory marker of short term glycemia
Article
Licensed
Unlicensed Requires Authentication

Labile glycated hemoglobin: an underestimated laboratory marker of short term glycemia

  • Joris R. Delanghe ORCID logo EMAIL logo , Stijn Lambrecht , Tom Fiers and Marijn M. Speeckaert
Published/Copyright: January 19, 2022

Abstract

Objectives

Diabetes mellitus is a major public health problem. Hemoglobin A1c (HbA1c) is a key laboratory parameter in the management of diabetes patients. However, in diabetes monitoring, interpretation of HbA1c results is hampered by the important interindividual variation in red blood cell (RBC) life span. Furthermore, HbA1c only slowly responds to changes in glucose metabolism. Besides HbA1c, there exists a labile HbA1c fraction (l-HbA1c), exhibiting much faster kinetics. As both HbA1c and l-HbA1c are measured by modern standard chromatography, we explored the possibilities of using the l-HbA1c fraction for monitoring glycemia.

Methods

l-HbA1c and HbA1c fractions were simultaneously assayed on a Tosoh G8 analyzer and expressed as %. l-HbA1c results were compared with serum glucose and HbA1c. Concomitantly, RBC distribution width (RDW) was determined on a Sysmex SN analyzer as a marker for erythrocyte life span.

Results

l-HbA1c could be measured with between-run coefficient of variations (CVs) between 2.2 and 2.3%. l-HbA1c correlated with both glycemia (r=0.80) and HbA1c results (r=0.73). In a multiple regression model (r2=0.752), glycemia and HbA1c were the most determining factors. To a lesser extent, RDW correlated with l-HbA1c (r=0.158). Furthermore, the l-HbA1c/HbA1c ratio weakly positively correlated with RDW (r=0.247).

Conclusions

L-HBA1c represents an additional marker for monitoring the rapid occurrence of glycemic disorders that escape detection when using only HbA1c and blood glucose. RDW can be used as an indicator of atypical RBCs life span, in which the l-HbA1c fraction may be helpful.


Corresponding author: Prof. Dr. Joris R. Delanghe, Department of Clinical Chemistry, Ghent University Hospital, C. Heymanslaan 10, 9000 Ghent, Belgium, Phone: +32 9 332 29 56, Fax: +32 9 332 36 59, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Not applicable.

  5. Ethical approval: Not applicable.

References

1. Bergman, M, Abdul-Ghani, M, DeFronzo, RA, Manco, M, Sesti, G, Fiorentino, TV, et al.. Review of methods for detecting glycemic disorders. Diabetes Res Clin Pract 2020;165:108233. https://doi.org/10.1016/j.diabres.2020.108233.Search in Google Scholar PubMed PubMed Central

2. Kohzuma, T, Tao, X, Koga, M. Glycated albumin as biomarker: evidence and its outcomes. J Diabetes Complicat 2021;35:108040. https://doi.org/10.1016/j.jdiacomp.2021.108040.Search in Google Scholar PubMed

3. León-Triana, O, Calvo, GF, Belmonte-Beitia, J, Rosa Durán, M, Escribano-Serrano, J, Michan-Doña, A, et al.. Labile haemoglobin as a glycaemic biomarker for patient-specific monitoring of diabetes: mathematical modelling approach. J R Soc Interface 2018;15:20180224.10.1098/rsif.2018.0224Search in Google Scholar PubMed PubMed Central

4. Corbé-Guillard, E, Jaisson, S, Pileire, C, Gillery, P. Labile hemoglobin A1c: unexpected indicator of preanalytical contraindications. Clin Chem 2011;57:340–1. https://doi.org/10.1373/clinchem.2010.152819.Search in Google Scholar PubMed

5. Morel, F, Henquet, S, Fondefréde, M. Labile or not labile: that is the question. Ann Biol Clin 2013;71:373–6. https://doi.org/10.1684/abc.2013.0829.Search in Google Scholar PubMed

6. Loh, TP, Peng, WK, Chen, L, Sethi, SK. Application of smoothed continuous labile haemoglobin A1c reference intervals for identification of potentially spurious HbA1c results. J Clin Pathol 2014;67:712–6. https://doi.org/10.1136/jclinpath-2014-202346.Search in Google Scholar PubMed

7. Koga, M, Kurebayashi, S, Murai, J, Saito, H, Miyazaki, A. Degree of discrepancy between HbA1c and glycemia in variant hemoglobin is smaller when HbA1c is measured by new-type Arkray HPLC compared with old-type HPLC. Clin Biochem 2014;47:123–5. https://doi.org/10.1016/j.clinbiochem.2013.09.019.Search in Google Scholar PubMed

8. Koga, M, Inada, S, Miyazaki, A. Identification of the presence of variant hemoglobin using a measurement of the labile HbA1c (# C) fraction. Ann Clin Lab Sci 2016;46:387–92.Search in Google Scholar

9. Cohen, RM, Franco, RS, Khera, PK, Smith, EP, Lindsell, CJ, Ciraolo, PJ, et al.. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008;112:4284–91. https://doi.org/10.1182/blood-2008-04-154112.Search in Google Scholar PubMed PubMed Central

10. Khera, PK, Smith, EP, Lindsell, CJ, Colleen Rogge, M, Haggerty, S, Wagner, DA, et al.. Use of an oral stable isotope label to confirm variation in red blood cell mean age that influences HbA1c interpretation. Am J Hematol 2015;90:50–5. https://doi.org/10.1002/ajh.23866.Search in Google Scholar PubMed PubMed Central

11. Nordin, G. Accuracy of HbA1c as monitored by external quality assessment and compared with patient mean values. J Diabetes Sci Technol 2018;12:771–9. https://doi.org/10.1177/1932296818785622.Search in Google Scholar PubMed PubMed Central

12. Jalali, MT, Bavarsad, SS, Hesam, S, Afsharmanesh, MR, Mohammadtaghvaei, N. Assessing agreement between the three common clinical measurement methods of HbA1c. J Diabetes Metab Disord 2020;19:273–9. https://doi.org/10.1007/s40200-020-00503-6.Search in Google Scholar PubMed PubMed Central

13. Park, SH, Park, CJ, Lee, BR, Kim, MJ, Han, MY, Cho, YU, et al.. Establishment of age-and gender-specific reference ranges for 36 routine and 57 cell population data items in a new automated blood cell Analyzer, Sysmex XN-2000. Ann Lab Med 2016;36:244–9. https://doi.org/10.3343/alm.2016.36.3.244.Search in Google Scholar PubMed PubMed Central

14. Alzahrani, N, Alouffi, S, Almutairi, K, Almutairi, M, Almutairi, T, Al Alwan, I, et al.. Can fasting blood sugar be used as an indicator of long-term diabetic control instead of estimated average glucose? Clin Lab 2020;66:12. https://doi.org/10.7754/Clin.Lab.2020.200324.Search in Google Scholar PubMed

15. Kawahara, R, Amemiya, T, Komori, T, Hirata, Y. The effect of blood glucose concentration on labile A1c in diabetic patients. Diabetes Care 1985;8:375–9. https://doi.org/10.2337/diacare.8.4.375.Search in Google Scholar PubMed

16. Salvagno, GL, Sanchis-Gomar, F, Picanza, A, Lippi, G. Red blood cell distribution width: a simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci 2015;52:86–105. https://doi.org/10.3109/10408363.2014.992064.Search in Google Scholar PubMed

17. Douglas, SW, Adamson, JW. The anemia of chronic disorders: studies of marrow regulation and iron metabolism. Blood 1975;45:55–65. https://doi.org/10.1182/blood.v45.1.55.55.Search in Google Scholar

18. Ricós, C, Alvarez, V, Cava, F, García-Lario, JV, Hernández, A, Jiménez, CV, et al.. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 1999;59:491–500.10.1080/00365519950185229Search in Google Scholar PubMed

19. Maese, JM, Fernández-Riejos, P, Sánchez Mora, C, de Toro, M, Menéndez Valladares, P, González-Rodriguez, C. Evaluation of Bio-Rad D-100 HbA1c analyzer against Tosoh G8 and Menarini HA-8180V Pract. Lab Med 2016;5:57–64.10.1016/j.plabm.2016.05.002Search in Google Scholar

20. Lin, MJ, Hoke, C, Ettinger, B, Coyne, RV. Technical performance evaluation of BM/Hitachi 747-200 serum fructosamine assay. Clin Chem 1996;42:244–8. https://doi.org/10.1093/clinchem/42.2.244.Search in Google Scholar

21. Weykamp, C, John, WG, Mosca, A, Hoshino, T, Little, R, Jeppsson, JO, et al.. The IFCC reference measurement system fo HbA1c: a 6-year progress report. Clin Chem 2008;54:240–8. https://doi.org/10.1373/clinchem.2007.097402.Search in Google Scholar PubMed

22. Nayak, AU, Holland, MR, Macdonald, DR, Nevill, A, Singh, BM. Evidence for consistency of the glycation gap in diabetes. Diabetes Care 2011;34:1712–6. https://doi.org/10.2337/dc10-1767.Search in Google Scholar PubMed PubMed Central

Received: 2022-01-03
Accepted: 2022-01-10
Published Online: 2022-01-19
Published in Print: 2022-02-23

© 2022 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Obituary
  3. Dr Per Hyltoft Petersen: an appreciation
  4. Editorials
  5. Extrapolated normative GFR data for living kidney donation
  6. Effectiveness of interventions to improve test appropriateness
  7. Reviews
  8. The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors
  9. S100B in cardiac surgery brain monitoring: friend or foe?
  10. Mini Review
  11. Blood lactate concentration in COVID-19: a systematic literature review
  12. Opinion Paper
  13. Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variants
  14. General Clinical Chemistry and Laboratory Medicine
  15. A randomized controlled study of biochemical tests in primary care: interventions can reduce the number of tests but usage does not become more appropriate
  16. A national surveillance program for evaluating new reagent lots in medical laboratories
  17. External quality assessment providers’ services appear to more impact the immunohaematology performance of laboratories than national regulatory and economic conditions
  18. International collaborative study to evaluate and calibrate two recombinant L chain Ferritin preparations for use as a WHO International Standard
  19. Method comparison of three serum free light chain assays on the Roche Cobas 6000 c501 chemistry analyzer
  20. Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients
  21. Analytical evaluation of the Nittobo Medical tartrate resistant acid phosphatase isoform 5b (TRACP-5b) EIA and comparison with IDS iSYS in different clinically defined populations
  22. Reference Values and Biological Variations
  23. Age-adapted percentiles of measured glomerular filtration in healthy individuals: extrapolation to living kidney donors over 65 years
  24. Indirectly determined hematology reference intervals for pediatric patients in Berlin and Brandenburg
  25. Hematology and Coagulation
  26. Monocyte distribution width (MDW): a useful biomarker to improve sepsis management in Emergency Department
  27. Diabetes
  28. A step towards optimal efficiency of HbA1c measurement as a first-line laboratory test: the TOP-HOLE (Towards OPtimal glycoHemOgLobin tEsting) project
  29. Labile glycated hemoglobin: an underestimated laboratory marker of short term glycemia
  30. Infectious Diseases
  31. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays
  32. Letters to the Editors
  33. Molecular detection of SARS-CoV-2 eta VOI in Northern Italy: a case report
  34. Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?
  35. Measurement in different sample types may aid in detecting interferences and macrocomplexes affecting cardiac troponin measurements
  36. Which method to detect macrotroponin?
  37. Marked geographical variation in the prevalence of macroprolactinemia
  38. Pancreatic lipase assays: time for a change towards immunoassays?
  39. Analytical evaluation of the performances of a new procalcitonin immunoassay
  40. Necessity of harmonization of tissue transglutaminase IgA assays to align clinical decision making in coeliac disease
  41. A fortuitous but characteristic blood smear observation allowing a late diagnosis of MPS-VII
  42. Prognostic significance of blood-based multi-cancer detection in plasma cell-free DNA
Downloaded on 11.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2021-1321/html?lang=en
Scroll to top button